Should oncologists trust cannabinoids?
- PMID: 37521486
- PMCID: PMC10373070
- DOI: 10.3389/fphar.2023.1211506
Should oncologists trust cannabinoids?
Abstract
Cannabis enjoyed a "golden age" as a medicinal product in the late 19th, early 20th century, but the increased risk of overdose and abuse led to its criminalization. However, the 21st century have witnessed a resurgence of interest and a large body of literature regarding the benefits of cannabinoids have emerged. As legalization and decriminalization have spread around the world, cancer patients are increasingly interested in the potential utility of cannabinoids. Although eager to discuss cannabis use with their oncologist, patients often find them to be reluctant, mainly because clinicians are still not convinced by the existing evidence-based data to guide their treatment plans. Physicians should prescribe cannabis only if a careful explanation can be provided and follow up response evaluation ensured, making it mandatory for them to be up to date with the positive and also negative aspects of the cannabis in the case of cancer patients. Consequently, this article aims to bring some clarifications to clinicians regarding the sometimes-confusing various nomenclature under which this plant is mentioned, current legislation and the existing evidence (both preclinical and clinical) for the utility of cannabinoids in cancer patients, for either palliation of the associated symptoms or even the potential antitumor effects that cannabinoids may have.
Keywords: anorexia and cachexia; anxiety and depression; cancer; cannabinoids; cannabis; nausea and vomiting; oncology; pain.
Copyright © 2023 Creanga-Murariu, Filipiuc, Cuciureanu, Tamba and Alexa-Stratulat.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Cannabis, Cannabinoids and Cannabis-Based Medicines in Cancer Care.Integr Cancer Ther. 2022 Jan-Dec;21:15347354221081772. doi: 10.1177/15347354221081772. Integr Cancer Ther. 2022. PMID: 35225051 Free PMC article. Review.
-
Medicinal cannabis in oncology.Eur J Cancer. 2007 Dec;43(18):2638-44. doi: 10.1016/j.ejca.2007.09.010. Epub 2007 Oct 31. Eur J Cancer. 2007. PMID: 17976975 Review.
-
[Cannabis and cannabinoids-easier access, hype and disappointment : What has been confirmed in therapy?].Internist (Berl). 2019 Mar;60(3):309-314. doi: 10.1007/s00108-019-0556-0. Internist (Berl). 2019. PMID: 30680416 Review. German.
-
Medical Cannabis in Oncology: a Valuable Unappreciated Remedy or an Undesirable Risk?Curr Treat Options Oncol. 2021 Jan 13;22(2):16. doi: 10.1007/s11864-020-00811-2. Curr Treat Options Oncol. 2021. PMID: 33439370 Review.
-
Cannabis for cancer - illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology.Expert Opin Investig Drugs. 2019 Mar;28(3):285-296. doi: 10.1080/13543784.2019.1561859. Epub 2018 Dec 29. Expert Opin Investig Drugs. 2019. PMID: 30572744 Review.
Cited by
-
Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs.Dtsch Arztebl Int. 2023 Dec 8;120(49):833-840. doi: 10.3238/arztebl.m2023.0223. Dtsch Arztebl Int. 2023. PMID: 37874128 Free PMC article. Review.
-
Immunotherapy and Cannabis: A Harmful Drug Interaction or Reefer Madness?Cancers (Basel). 2024 Mar 22;16(7):1245. doi: 10.3390/cancers16071245. Cancers (Basel). 2024. PMID: 38610922 Free PMC article.
-
The potential neuroprotective effects of cannabinoids against paclitaxel-induced peripheral neuropathy: in vitro study on neurite outgrowth.Front Pharmacol. 2024 Jun 12;15:1395951. doi: 10.3389/fphar.2024.1395951. eCollection 2024. Front Pharmacol. 2024. PMID: 38933665 Free PMC article.
-
Recent Advances in Neuroblastoma Research.Cancers (Basel). 2024 Feb 17;16(4):812. doi: 10.3390/cancers16040812. Cancers (Basel). 2024. PMID: 38398203 Free PMC article.
References
-
- Adams R., Hunt M., Clark J. H. (1940). Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I. . J. Am. Chem. Soc. 62 (1), 196–200. 10.1021/ja01858a058 - DOI
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials